• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Safety and Efficacy Conerns in the Use of Intravitreal Anti-VEGF Therapy (Sponsored)

Article

This supplement to Ophthalmology Times is sponsored by CME Matters, LLC, and supported by an unrestricted grant from Regeneron Pharmaceuticals, Inc.

 

Safety and Efficacy Conerns in the
Use of Intravitreal Anti-VEGF Therapy

The Historical Perspective on
Efficacy and Systemic Safety


This supplement to Ophthalmology Times is sponsored by CME Matters, LLC, and supported by an unrestricted grant from Regeneron Pharmaceuticals, Inc.
 

 

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.